- RETA Stock Soars as FDA Approves Reata Phama’s Neurological Drug | Investor Business DailyInvestor Business Daily
- FDA expands pathway for rare disease treatments with new approvalThe Wall Street Journal
- Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxiabusiness thread
- FDA approves Reata’s treatment for rare neurological conditionSTAT
- Reata Pharmaceuticals Friedreich’s ataxia drug omaveloxolone gains FDA approval (RETA)Looking for Alpha
- See full coverage on Google News